Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1996 1
1998 1
1999 1
2006 2
2010 1
2011 5
2012 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Oral rivaroxaban for symptomatic venous thromboembolism.
EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. EINSTEIN Investigators, et al. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. N Engl J Med. 2010. PMID: 21128814 Free article. Clinical Trial.
CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. ...
CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that ma …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. ...
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of …
Management of venous thromboembolism.
de Moerloose P, Samama CM, Motte S. de Moerloose P, et al. Among authors: motte s. Can J Anaesth. 2006 Jun;53(6 Suppl):S80-8. doi: 10.1007/BF03022255. Can J Anaesth. 2006. PMID: 16766793 Review.
The duration of oral anticoagulation must be tailored to the individual patient according to the presence of reversible or continuing risk factors. In patients with active cancer, long-term treatment of VTE with LMWH has been shown to be more effective than oral anticoagul …
The duration of oral anticoagulation must be tailored to the individual patient according to the presence of reversible or continuing risk f …
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Goldhaber SZ, et al. N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899. Epub 2011 Nov 13. N Engl J Med. 2011. PMID: 22077144 Free article. Clinical Trial.
We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. METHODS: In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart f …
We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. …
[Diagnosis and treatment of pulmonary embolism].
Motte S. Motte S. Rev Med Brux. 2006 Jan-Feb;27(1):21-7. Rev Med Brux. 2006. PMID: 16608008 Review. French.
Initial treatment for patients with non massive PE consists of therapeutic anti-coagulation with low molecular weight heparin (LMWH) and early overlapping with oral anticoagulants. In patients with active cancer, long-term treatment with LMWH is recommended. Duration of an …
Initial treatment for patients with non massive PE consists of therapeutic anti-coagulation with low molecular weight heparin (LMWH) and ear …
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P; Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis. Sié P, et al. Arch Cardiovasc Dis. 2011 Dec;104(12):669-76. doi: 10.1016/j.acvd.2011.09.001. Epub 2011 Oct 29. Arch Cardiovasc Dis. 2011. PMID: 22152517 Free article.
Direct oral anticoagulants (DOAs)--inhibitors of thrombin or factor-Xa--are expected to replace vitamin K antagonists in most of their indications. Patients receiving long-term treatment with DOAs are likely to be exposed to elective or emergency surgery or invasive proced …
Direct oral anticoagulants (DOAs)--inhibitors of thrombin or factor-Xa--are expected to replace vitamin K antagonists in most of their indic …
Retention of movement pattern changes after a lower extremity injury prevention program is affected by program duration.
Padua DA, DiStefano LJ, Marshall SW, Beutler AI, de la Motte SJ, DiStefano MJ. Padua DA, et al. Among authors: de la motte sj. Am J Sports Med. 2012 Feb;40(2):300-6. doi: 10.1177/0363546511425474. Epub 2011 Nov 7. Am J Sports Med. 2012. PMID: 22064608 Clinical Trial.
CONCLUSION: Results suggest that training duration may be an important factor to consider when designing injury prevention programs that facilitate long-term changes in movement control....
CONCLUSION: Results suggest that training duration may be an important factor to consider when designing injury prevention programs that fac …
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE; Cassiopea Investigators. Büller HR, et al. Lancet. 2012 Jan 14;379(9811):123-9. doi: 10.1016/S0140-6736(11)61505-5. Epub 2011 Nov 28. Lancet. 2012. PMID: 22130488 Clinical Trial.
INTERPRETATION: Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolism, and seems to be associated with reduced bleeding. ...
INTERPRETATION: Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolis …
Non-linear pharmacokinetic modelling of intravenous elgodipine.
de la Motte S, Alberich X, Harrison F. de la Motte S, et al. Int J Clin Pharmacol Ther. 1999 Jan;37(1):20-7. Int J Clin Pharmacol Ther. 1999. PMID: 10027479 Clinical Trial.
Non-compartmental and compartmental evaluations were made. A two-compartment model with lag time and Michaelis-Menten term for elimination was found to be appropriate. RESULTS: Based on Michaelis-Menten parameters and concentration time courses during infusions, the elimin …
Non-compartmental and compartmental evaluations were made. A two-compartment model with lag time and Michaelis-Menten term for elimin …
Occluding aortic endoluminal stent graft combined with extra-anatomic axillofemoral bypass as alternative management of abdominal aortic aneurysms for patients at high risk with complex anatomic features: a preliminary report.
Le Minh T, Motte S, Hoang AD, Ferreira J, Golzarian J, Dehon P, Cavenaile JC, Michel P, Guyot S, Giot C, Wautrecht JC, Dereume JP. Le Minh T, et al. Among authors: motte s. J Vasc Surg. 1998 Oct;28(4):651-6. doi: 10.1016/s0741-5214(98)70090-4. J Vasc Surg. 1998. PMID: 9786260 Free article.
CONCLUSIONS: Placement of an occluding endograft associated with axillofemoral bypass grafting is a good alternative for patients at high risk with complex anatomic features. Longer-term follow-up study is needed to evaluate this endoluminal technique....
CONCLUSIONS: Placement of an occluding endograft associated with axillofemoral bypass grafting is a good alternative for patients at high ri …
13 results